Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Shares Repurchased (2019 - 2025)

Historic Shares Repurchased for C4 Therapeutics (CCCC) over the last 5 years, with Q3 2025 value amounting to $24000.0.

  • C4 Therapeutics' Shares Repurchased fell 7176.47% to $24000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $334000.0, marking a year-over-year increase of 1023.1%. This contributed to the annual value of $194000.0 for FY2024, which is 7636.36% up from last year.
  • According to the latest figures from Q3 2025, C4 Therapeutics' Shares Repurchased is $24000.0, which was down 7176.47% from $155000.0 recorded in Q1 2025.
  • C4 Therapeutics' 5-year Shares Repurchased high stood at $155000.0 for Q1 2025, and its period low was $16000.0 during Q3 2023.
  • For the 3-year period, C4 Therapeutics' Shares Repurchased averaged around $80500.0, with its median value being $89500.0 (2023).
  • In the last 5 years, C4 Therapeutics' Shares Repurchased skyrocketed by 43125.0% in 2024 and then crashed by 7176.47% in 2025.
  • Over the past 3 years, C4 Therapeutics' Shares Repurchased (Quarter) stood at $16000.0 in 2023, then skyrocketed by 431.25% to $85000.0 in 2024, then tumbled by 71.76% to $24000.0 in 2025.
  • Its Shares Repurchased was $24000.0 in Q3 2025, compared to $155000.0 in Q1 2025 and $85000.0 in Q3 2024.